

strain A/VN/1203/2004 (H5N1) using a cell-based HTS assay. The screen yielded five active compounds (SI50 value >3) representing two different classes of molecules, benzoquinazolinones and thiazoloimidazoles, which have not been previously identified as having anti-viral/anti-influenza activity. Subsequent synthetic work led to novel second-generation compounds with improved potency and solubility. Several compounds displayed significant antiviral activity with low EC₅₀ values (nM range) without significant toxicity and high selectivity (SI50 > 3125) in MDCK cells. Time of addition experiments revealed that seven of these compounds inhibited an event early in the virus life cycle; suggesting they may affect entry. We screened our lead compound, SRI 22521, against 14 influenza A and B viruses in MDCK cells to establish its spectrum of activity. The compound was highly active against H1N1 and H5N1 viruses, but not active against H3N2 and B viruses. Preliminary neuraminidase assays reveal that SRI 22521 did not inhibit viral neuraminidase. Given the promising in vitro activity of SRI 22521, we examined its efficacy at 100 mg/kg of body weight/day (two times a day) for 5 days in mice challenged with 10LD₅₀ of influenza virus A/VN/1203/2004. We noted a reduction in the rate of mortality in mice challenged with virus. Experimental results with this compound indicate that improving the solubility characteristics of this compound will be beneficial and work toward generating such compounds is in progress. We continue to explore the mechanism of action of this new and promising scaffold.

doi:10.1016/j.antiviral.2009.02.073

68

Rimantadine and Oseltamivir Combination Effects in a Therapeutic Course of Application Against Influenza A (H3N2) in Mice

Lora Simeonova*, Galina Gegova, Angel S. Galabov

Institute of Microbiology, Bulg. Acad. Sci., Sofia, Bulgaria

Our previous studies demonstrated a marked synergistic combination effect of rimantadine and oseltamivir in 25:1 dose ratio in experimental infection with influenza A (H3N2) in mice when the treatment course begins on the day of virus inoculation (v.i.). Here we studied effect of both compounds in the same ratio and in optimal doses applied 24 h post v.i. in order to determine if the efficacy of combined therapy is preserved when the disease is already in progress which is the situation closer to the real conditions in patients. White male mice 16–18 g were inoculated intranasally with 0.05 ml/mouse of influenza A/Aichi/2/68 (H3N2) virus. Rimantadine hydrochloride and oseltamivir phosphate were administered per os twice daily in 5-day-treatment course beginning 24 h after v.i. with 10–20 MLD₅₀. Protection index (PI) and mean survival time (MST) were determined through 14 days post v.i. Combinations of 5, 10, 20, 40 and 80 mg/kg/day rimantadine and 0.2, 0.4, 0.8, 1.6 and 3.2 mg/kg/day oseltamivir were combined in doses ratio 25:1. The effects of 5 mg/kg oseltamivir + 40 mg/kg rimantadine and 10 mg/kg oseltamivir with 80 mg/kg rimantadine were studied, too. Combinations of 0.8 mg/kg oseltamivir + 20 mg/kg rimantadine, 1.6 mg/kg oseltamivir + 40 mg/kg rimantadine and 3.2 mg/kg oseltamivir + 80 mg/kg rimantadine demonstrated marked protective effects: PI values of 63.9%, 79.7% and 82.6% and MST of 12.8, 13.3 and 13.7 days, while the compounds' effects administered separately at the same doses vary from 15.7% to maximum 46.3% PI and 8.9 to 12.8 days MST. MST values in the placebo were 8.7 days. Combinations of 0.2 and 0.4 mg/kg oseltamivir with 5 and 10 mg/kg rimantadine, respectively, showed no protective effect. 5 mg oseltamivir + 40 mg rimantadine and 10 mg oseltamivir + 80 rimantadine combinations exert strong protective effect: 94.5% PI and 13.9 days MST and 100% PI and MST more than 14 days, respec-

tively. Combination of oseltamivir and rimantadine in 1:25 dose ratio as well as in optimal in vivo doses administered in a therapeutic course (onset 24 h post virus inoculation) demonstrated a marked synergistic protective effect in mice experimentally infected with influenza virus A (H3N2).

doi:10.1016/j.antiviral.2009.02.074

69

Combination of Neuraminidase Inhibitors with T-705 for Treating Influenza Virus Infections in Cell Culture and in Mice

Donald Smee^{1,*}, Min-Hui Wong¹, Kevin Bailey¹, John Morrey¹, Masako Maekawa², Kazumi Takahashi², Yousuke Furuta²

¹Utah State University, Logan, USA; ²Toyama Chemical Co. Ltd., Toyama, Japan

Effective treatment of influenza virus infections remains a public health priority. Use of combinations of antiviral compounds may increase efficacy and reduce the frequency of emergence of drug-resistant viruses. The viral neuraminidase inhibitors oseltamivir (an in vivo prodrug, or its active form oseltamivir carboxylate) and/or zanamivir were combined with T-705 (6-fluoro-3-hydroxy-2-pyrazinocarboxamide, currently in clinical trials) to treat infections in cell culture and in mice. MDCK cells were infected with influenza A/PR/8/34 (H1N1) and A/Victoria/3/75 (H3N2) viruses and treated with varying combinations of compounds. Additive to synergistic interactions was evaluated based upon reductions in viral cytopathology. These studies indicated several combinations of oseltamivir carboxylate or zanamivir with T-705 at low micromolar concentrations produced synergistic responses against both virus infections. Later, drug combination studies were conducted in BALB/c mice infected intranasally with influenza A/NWS/33 (H1N1), A/Victoria/3/75 (H3N2), and A/Duck/MN/1525/81 (H5N1) viruses using oseltamivir and T-705. Oral treatments were given twice a day for 5 (A/NWS infection) or 7 (A/Victoria and A/Duck infections) days starting 24 h after virus exposure. Synergistic activity was observed at the lower doses (20–25 mg/kg/day) of T-705, as determined by increases in numbers of survivors. Use of oseltamivir and T-705 in combination in the clinic may be warranted. [Supported in part by NIAID contracts NO1-AI-15435, NO1-AI-30048, and NO1-AI-30063.]

doi:10.1016/j.antiviral.2009.02.075

70

High Throughput Screening of Protease Inhibitor Libraries Using a Novel Dual Pseudotype-Based Assay for SARS-CoV Entry

Yanchen Zhou*, Kai Lu, Juliet Agudelo, Graham Simmons

Blood Systems Research Institute, and University of California, San Francisco, USA

The severe acute respiratory syndrome-associated coronavirus (SARS-CoV) recently emerged as the causal agent of an endemic atypical pneumonia, infecting thousands of people worldwide. We describe here a rapid and safe high-throughput assay for specifically screening for inhibitors of viral entry, using lentiviral pseudovirions whose entry is driven by SARS-CoV Spike glycoprotein. In preliminary studies, we found that many initial hits identified as potential inhibitors of entry mediated by SARS-CoV Spike, were also able to inhibit other pH-dependent viruses, likely due to gross effects on cellular function. In order to overcome this obstacle, in the same well, a second, unrelated pH-dependent viral envelope in conjunction with a lentiviral vector encoding a different reporter gene is